$ITCI
Intra-Cellular Therapies, Inc.

2015 Q3 Form 10-Q Financial Statement

#000119312515278745 Filed on August 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00 $57.39K $219.2K
YoY Change -100.0% -73.82% -65.92%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.890M $3.990M $2.120M
YoY Change 50.78% 88.21% 135.56%
% of Gross Profit
Research & Development $28.46M $17.76M $2.710M
YoY Change 603.29% 555.52% -65.21%
% of Gross Profit
Depreciation & Amortization $40.00K $30.00K $6.430K
YoY Change 524.12% 366.56% -35.7%
% of Gross Profit
Operating Expenses $32.35M $21.75M $2.710M
YoY Change 699.47% 702.61% -65.21%
Operating Profit -$32.35M -$21.69M -$4.612M
YoY Change 397.41% 370.36% -42.7%
Interest Expense $190.0K $180.0K $2.032K
YoY Change 8758.27% -99.12%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$32.16M -$21.51M -$4.530M
YoY Change 400.94% 374.83% -45.29%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$32.16M -$21.51M -$4.534M
YoY Change 401.29% 374.49% -45.23%
Net Earnings / Revenue -37482.69% -2067.86%
Basic Earnings Per Share
Diluted Earnings Per Share -$910.5K -$614.6K -$154.8K
COMMON SHARES
Basic Shares Outstanding 35.06M shares 34.97M shares 29.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $510.7M $204.0M $140.5M
YoY Change 275.51% 45.2% 1264.08%
Cash & Equivalents $332.8M $71.42M $91.14M
Short-Term Investments $177.9M $132.6M $49.40M
Other Short-Term Assets $1.500M $8.600M $500.0K
YoY Change 7.14% 1620.0% 400.0%
Inventory
Prepaid Expenses
Receivables $0.00 $9.118K $219.2K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $512.3M $212.6M $141.2M
YoY Change 272.61% 50.57% 1219.7%
LONG-TERM ASSETS
Property, Plant & Equipment $785.5K $722.1K $63.85K
YoY Change 1267.59% 1030.98% -36.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $71.88K $70.94K $70.94K
YoY Change 1.31% 0.0% -29.06%
Total Long-Term Assets $857.4K $793.1K $134.8K
YoY Change 567.86% 488.36% -32.6%
TOTAL ASSETS
Total Short-Term Assets $512.3M $212.6M $141.2M
Total Long-Term Assets $857.4K $793.1K $134.8K
Total Assets $513.1M $213.4M $141.3M
YoY Change 272.88% 50.98% 1196.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $705.0K $4.911M $415.8K
YoY Change 39.92% 1081.14% -85.15%
Accrued Expenses $9.700M $4.400M $2.300M
YoY Change 212.9% 91.3% -39.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.39M $9.318M $2.739M
YoY Change 190.33% 240.17% -87.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $900.0K $500.0K
YoY Change
Total Long-Term Liabilities $900.0K $500.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.39M $9.318M $2.739M
Total Long-Term Liabilities $900.0K $500.0K $0.00
Total Liabilities $11.27M $9.839M $2.700M
YoY Change 213.0% 264.4% -88.11%
SHAREHOLDERS EQUITY
Retained Earnings -$164.2M -$132.1M -$66.64M
YoY Change 124.78% 98.16%
Common Stock $666.1M $335.7M $2.934K
YoY Change 22655958.71% 11440666.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $501.9M $203.6M $138.6M
YoY Change
Total Liabilities & Shareholders Equity $513.1M $213.4M $141.3M
YoY Change 272.88% 50.98% 1196.72%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$32.16M -$21.51M -$4.534M
YoY Change 401.29% 374.49% -45.23%
Depreciation, Depletion And Amortization $40.00K $30.00K $6.430K
YoY Change 524.12% 366.56% -35.7%
Cash From Operating Activities -$20.51M -$31.00M -$5.200M
YoY Change 364.03% 496.15% -43.48%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$190.0K -$10.00K
YoY Change 1800.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$45.48M $1.640M -$47.44M
YoY Change 154.93% -103.46% -3262.67%
Cash From Investing Activities -$45.58M $1.440M -$47.45M
YoY Change 155.49% -103.03% -3284.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $345.2M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 327.5M 170.0K 170.0K
YoY Change 1091600.0% 0.0% -57.5%
NET CHANGE
Cash From Operating Activities -20.51M -31.00M -5.200M
Cash From Investing Activities -45.58M 1.440M -47.45M
Cash From Financing Activities 327.5M 170.0K 170.0K
Net Change In Cash 261.4M -29.39M -52.48M
YoY Change -1275.98% -44.0% 617.92%
FREE CASH FLOW
Cash From Operating Activities -$20.51M -$31.00M -$5.200M
Capital Expenditures -$110.0K -$190.0K -$10.00K
Free Cash Flow -$20.40M -$30.81M -$5.190M
YoY Change 361.54% 493.64% -43.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-46713772
CY2014Q1 us-gaap Share Price
SharePrice
17.50
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35056246 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91140138
CY2015Q1 itci Area Of Office Space Leased
AreaOfOfficeSpaceLeased
16753 sqft
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2908069 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.31
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35041746 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.31
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1356039 shares
CY2015Q2 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
1.00 pure
CY2015Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20100000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35041746 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.75
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2908069 shares
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
335668581
CY2015Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1066629
CY2015Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3340399
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
203565309
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
520628
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4911065
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132054099
CY2015Q2 us-gaap Liabilities
Liabilities
9838721
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
213404030
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
3504
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2264333
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9318093
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-52677
CY2015Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
132570900
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70944
CY2015Q2 us-gaap Assets
Assets
213404030
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
66000
CY2015Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
189474000
CY2015Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9118
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
722131
CY2015Q2 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
44700000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
212610955
CY2015Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
14400000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8612651
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71418286
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2986464
CY2015Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
132623000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35150924
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2233460 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.20
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29499059 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29499059 shares
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
208912345
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
975058
CY2014Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7529241
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
120554705
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2052765
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-88255957
CY2014Q4 us-gaap Liabilities
Liabilities
10557064
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131111769
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2950
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2228413
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10557064
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104633
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
68320672
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70944
CY2014Q4 us-gaap Assets
Assets
131111769
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
106000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
115815000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
51603
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54553
CY2014Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
31800000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
130986272
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
8500000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1288953
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61325044
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2282966
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
68425000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7063300 shares
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
115400000
CY2014Q1 itci Share Issued During Period Shares Underwriters New Issues
ShareIssuedDuringPeriodSharesUnderwritersNewIssues
921300 shares
CY2015Q1 itci Net Proceeds From Initial Public Offering
NetProceedsFromInitialPublicOffering
121800000
CY2015Q1 itci Share Issued During Period Shares Underwriters New Issues
ShareIssuedDuringPeriodSharesUnderwritersNewIssues
661481 shares
CY2015Q2 itci Registration Statement Filing Date
RegistrationStatementFilingDate
2015-05-28
CY2015Q2 itci Period After Filing Shelf Registration Statement Expires
PeriodAfterFilingShelfRegistrationStatementExpires
P3Y
CY2015Q2 itci Entity Securities Universal Shelf Registration
EntitySecuritiesUniversalShelfRegistration
350000000
CY2014Q3 itci Registration Statement Filing Date
RegistrationStatementFilingDate
2014-08-29
CY2014Q3 itci Entity Securities Universal Shelf Registration
EntitySecuritiesUniversalShelfRegistration
150000000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12180313
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27882360 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8325
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
us-gaap Net Income Loss
NetIncomeLoss
-9076823
us-gaap Revenues
Revenues
387025
us-gaap Interest Paid
InterestPaid
7073
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-329498
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
748538
us-gaap Operating Income Loss
OperatingIncomeLoss
-9186047
us-gaap Income Taxes Paid
IncomeTaxesPaid
27866
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
72444786
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-41753
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-117080
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9124572
us-gaap Investment Income Interest
InvestmentIncomeInterest
116297
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-47749
us-gaap Share Based Compensation
ShareBasedCompensation
490215
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9573072
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
55989214
us-gaap Interest Expense
InterestExpense
7073
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-47453111
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
25000000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
115622638
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5539001
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
116191285
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1115507
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
70058
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4034071
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2979276
us-gaap Depreciation
Depreciation
12747
itci Proceeds From Common Stock Subscribed
ProceedsFromCommonStockSubscribed
109833
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Intra-Cellular Therapies, Inc.
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.33
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001567514
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.04
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
13500 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
127864 shares
dei Trading Symbol
TradingSymbol
ITCI
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32900731 shares
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
us-gaap Net Income Loss
NetIncomeLoss
-43798142
us-gaap Revenues
Revenues
60705
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7323698
itci Available For Sale Securities Maturity Period
AvailableForSaleSecuritiesMaturityPeriod
More than three months
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
815973 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
714698
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
278643
us-gaap Operating Income Loss
OperatingIncomeLoss
-44091665
us-gaap Income Taxes Paid
IncomeTaxesPaid
206600
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
93670933
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-344863
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42485
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43746186
us-gaap Investment Income Interest
InvestmentIncomeInterest
293523
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
51956
us-gaap Share Based Compensation
ShareBasedCompensation
4600605
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
44152370
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10093242
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
520628
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-65257833
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
29127798
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
122064847
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36394945
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
122083012
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4097271
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
260478
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7757425
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
91338
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2858300
us-gaap Depreciation
Depreciation
47120
itci Share Based Compensation Arrangement By Share Based Payment Award Canceled Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceledWeightedAverageRemainingContractualTerm
P7Y10M24D
itci Maturity Period Of Liquid Investments To Be Considered As Cash Equivalents
MaturityPeriodOfLiquidInvestmentsToBeConsideredAsCashEquivalents
Three months or less
itci Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm
P3Y
itci Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2
P9Y7M6D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015Q1 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P11Y
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29273357 shares
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-4533539
CY2014Q2 us-gaap Revenues
Revenues
219238
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4611584
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4581288
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
80077
CY2014Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-47749
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
290461
CY2014Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
4830822
CY2014Q2 us-gaap Interest Expense
InterestExpense
2032
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2709702
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2121120
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35002819 shares
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-21511318
CY2015Q2 us-gaap Revenues
Revenues
57390
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21690925
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21530091
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
179607
CY2015Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-18773
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2500779
CY2015Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21748315
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17762518
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3985797

Files In Submission

Name View Source Status
0001193125-15-278745-index-headers.html Edgar Link pending
0001193125-15-278745-index.html Edgar Link pending
0001193125-15-278745.txt Edgar Link pending
0001193125-15-278745-xbrl.zip Edgar Link pending
d12763d10q.htm Edgar Link pending
d12763dex311.htm Edgar Link pending
d12763dex312.htm Edgar Link pending
d12763dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
itci-20150630.xml Edgar Link completed
itci-20150630.xsd Edgar Link pending
itci-20150630_cal.xml Edgar Link unprocessable
itci-20150630_def.xml Edgar Link unprocessable
itci-20150630_lab.xml Edgar Link unprocessable
itci-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending